Quantcast
Last updated on April 24, 2014 at 5:30 EDT

BioBDx to Present at the 2011 BioPharm America Conference

August 31, 2011

PLYMOUTH MEETING, Pa., Aug. 31, 2011 /PRNewswire/ — BioBDx announced today that the Company’s Chairman and CEO Byron Hewett will present at the 2011 BioPharm America Conference taking place September 7-9. BioBDx manufactures and markets the Quotient® System, a tool that objectively measures brain functions related to deficits in response inhibition. The first FDA-cleared application of this platform technology is objective measurement of hyperactivity, impulsivity and inattention as an aid in the assessment of attention-deficit hyperactivity disorder (ADHD). Mr. Hewett will provide a company overview and update on the Quotient ADHD System on Thursday, September 8 at 4:15 p.m. EDT in the Otis room at the Westin Boston Waterfront Hotel in Boston, MA.

About the Quotient® ADHD Test

The Quotient® ADHD Test measures motion and analyzes shifts in attention state to give an objective picture of the core symptom areas of ADHD. Clinicians use the Quotient® ADHD Test at the initial visit to assess severity of the three core symptoms of ADHD; hyperactivity, inattention and impulsivity. Patients may be re-assessed periodically at follow-up visits to guide treatment plans. The clinician integrates the Quotient® ADHD Test report with information from other assessment tools and the clinical evaluation to help guide the discussion on the treatment plan. For more information about the Quotient® ADHD System, please visit http://www.biobdx.com/products

About BioBehavioral Diagnostics Company

BioBDx manufactures and markets the Quotient System, a tool that aids in the objective and accurate assessment of neural control functions related to deficits in inhibitory control. We are dedicated to providing physicians, parents and patients with high-value information to guide personalized strategies and to enhance quality of life for patients with ADHD. Our vision is to provide accurate tools for the diagnosis and management of neurological and psychiatric conditions, leading to a transformation of behavioral medicine. Founded in 2006, BioBehavioral Diagnostics is a privately held company.


    Contacts:
    BioBDx                               Media or Investors:
    Byron Hewett                         Tiberend Strategic Advisors, Inc.
    Chairman and Chief Executive Officer 212-827-0020
    484-532-2201                         Tamara Bright
    Byron_Hewett@BioBDx.com              tbright@tiberend.com or
                                         Claire Sojda
                                         csojda@tiberend.com

SOURCE BioBDx


Source: PR Newswire